BRAF and neoplasm: Furthermore, serial assessments of PD-L1 expression in larger cohorts have shown that expression levels can fluctuate over time, particularly in response to prior therapies such as anti-BRAF/MEK inhibitors, which could alter the tumor’s immunogenicity [59].